Nathan Pennell, MD, PhD

Nathan Pennell, MD, PhD, director, Lung Cancer Medical Oncology Program, Cleveland Clinic Taussig Cancer Institute, discusses the economic impact of next-generation sequencing.

Nathan Pennell, MD, PhD, medical oncologist, Department of Hematology and Oncology, Cleveland Clinic, discusses some of the rare toxicities seen in patients with lung cancer.

Nathan Pennell, MD, PhD, associate professor of Medicine at Cleveland Clinic, discusses the importance of testing patients with non–small cell lung cancer (NSCLC) to determine if they harbor the EGFR mutation, as well as the agents available to target that genetic abnormality.